117 related articles for article (PubMed ID: 35349735)
21. Activation of beta-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis.
Liu L; Zhu XD; Wang WQ; Shen Y; Qin Y; Ren ZG; Sun HC; Tang ZY
Clin Cancer Res; 2010 May; 16(10):2740-50. PubMed ID: 20460486
[TBL] [Abstract][Full Text] [Related]
22. β-catenin alteration is rare in hepatocellular carcinoma with steatohepatitic features: immunohistochemical and mutational study.
Ando S; Shibahara J; Hayashi A; Fukayama M
Virchows Arch; 2015 Nov; 467(5):535-42. PubMed ID: 26311355
[TBL] [Abstract][Full Text] [Related]
23. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.
Deng L; Sun J; Chen X; Liu L; Wu D
J Exp Clin Cancer Res; 2019 Jul; 38(1):316. PubMed ID: 31319849
[TBL] [Abstract][Full Text] [Related]
24. PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation.
Liu Y; Ye X; Zhang JB; Ouyang H; Shen Z; Wu Y; Wang W; Wu J; Tao S; Yang X; Qiao K; Zhang J; Liu J; Fu Q; Xie Y
Oncogene; 2015 Oct; 34(44):5524-35. PubMed ID: 25684142
[TBL] [Abstract][Full Text] [Related]
25. The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma.
Zeng SS; Yamashita T; Kondo M; Nio K; Hayashi T; Hara Y; Nomura Y; Yoshida M; Hayashi T; Oishi N; Ikeda H; Honda M; Kaneko S
J Hepatol; 2014 Jan; 60(1):127-34. PubMed ID: 24012616
[TBL] [Abstract][Full Text] [Related]
26. Galectin-3 favours tumour metastasis via the activation of β-catenin signalling in hepatocellular carcinoma.
Song M; Pan Q; Yang J; He J; Zeng J; Cheng S; Huang Y; Zhou ZQ; Zhu Q; Yang C; Han Y; Tang Y; Chen H; Weng DS; Xia JC
Br J Cancer; 2020 Nov; 123(10):1521-1534. PubMed ID: 32801345
[TBL] [Abstract][Full Text] [Related]
27. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
28. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
Lachenmayer A; Alsinet C; Savic R; Cabellos L; Toffanin S; Hoshida Y; Villanueva A; Minguez B; Newell P; Tsai HW; Barretina J; Thung S; Ward SC; Bruix J; Mazzaferro V; Schwartz M; Friedman SL; Llovet JM
Clin Cancer Res; 2012 Sep; 18(18):4997-5007. PubMed ID: 22811581
[TBL] [Abstract][Full Text] [Related]
29. Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells.
Yuzugullu H; Benhaj K; Ozturk N; Senturk S; Celik E; Toylu A; Tasdemir N; Yilmaz M; Erdal E; Akcali KC; Atabey N; Ozturk M
Mol Cancer; 2009 Oct; 8():90. PubMed ID: 19849855
[TBL] [Abstract][Full Text] [Related]
30. Hepatocellular Carcinoma Score and Subclassification Into Aggressive Subtypes Using Immunohistochemical Expression of p53, β-Catenin, CD133, and Ki-67.
Abdou AG; Holah NS; Elazab DS; El-Gendy WG; Badr MT; Al-Sharaky DR
Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):20-33. PubMed ID: 32287076
[TBL] [Abstract][Full Text] [Related]
31. Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma.
Gérard C; Di-Luoffo M; Gonay L; Caruso S; Couchy G; Loriot A; Castven D; Tao J; Konobrocka K; Cordi S; Monga SP; Hanert E; Marquardt JU; Zucman-Rossi J; Lemaigre FP
J Hepatol; 2019 Aug; 71(2):323-332. PubMed ID: 30953666
[TBL] [Abstract][Full Text] [Related]
32. Expression of NKG2D ligands is downregulated by β-catenin signalling and associates with HCC aggressiveness.
Cadoux M; Caruso S; Pham S; Gougelet A; Pophillat C; Riou R; Loesch R; Colnot S; Nguyen CT; Calderaro J; Celton-Morizur S; Guerra N; Zucman-Rossi J; Desdouets C; Couty JP
J Hepatol; 2021 Jun; 74(6):1386-1397. PubMed ID: 33484773
[TBL] [Abstract][Full Text] [Related]
33. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.
Tao J; Krutsenko Y; Moghe A; Singh S; Poddar M; Bell A; Oertel M; Singhi AD; Geller D; Chen X; Lujambio A; Liu S; Monga SP
Hepatology; 2021 Aug; 74(2):741-759. PubMed ID: 33529367
[TBL] [Abstract][Full Text] [Related]
34. Suppression of Slit3 induces tumor proliferation and chemoresistance in hepatocellular carcinoma through activation of GSK3β/β-catenin pathway.
Ng L; Chow AKM; Man JHW; Yau TCC; Wan TMH; Iyer DN; Kwan VHT; Poon RTP; Pang RWC; Law WL
BMC Cancer; 2018 Jun; 18(1):621. PubMed ID: 29859044
[TBL] [Abstract][Full Text] [Related]
35. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.
Hoshida Y; Nijman SM; Kobayashi M; Chan JA; Brunet JP; Chiang DY; Villanueva A; Newell P; Ikeda K; Hashimoto M; Watanabe G; Gabriel S; Friedman SL; Kumada H; Llovet JM; Golub TR
Cancer Res; 2009 Sep; 69(18):7385-92. PubMed ID: 19723656
[TBL] [Abstract][Full Text] [Related]
36. MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma.
Xia H; Ooi LL; Hui KM
PLoS One; 2012; 7(9):e44206. PubMed ID: 22962603
[TBL] [Abstract][Full Text] [Related]
37. SPAG5 promotes hepatocellular carcinoma progression by downregulating SCARA5 through modifying β-catenin degradation.
Liu H; Hu J; Wei R; Zhou L; Pan H; Zhu H; Huang M; Luo J; Xu W
J Exp Clin Cancer Res; 2018 Sep; 37(1):229. PubMed ID: 30249289
[TBL] [Abstract][Full Text] [Related]
38. Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/β-catenin pathway.
Lo RC; Leung CO; Chan KK; Ho DW; Wong CM; Lee TK; Ng IO
Cell Death Differ; 2018 Aug; 25(8):1426-1441. PubMed ID: 29445127
[TBL] [Abstract][Full Text] [Related]
39. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
Chen X; Hu G; Xiong L; Xu Q
Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
[No Abstract] [Full Text] [Related]
40. Hepatic cancer stem cell marker granulin-epithelin precursor and β-catenin expression associate with recurrence in hepatocellular carcinoma.
Cheung PF; Cheung TT; Yip CW; Ng LW; Fung SW; Lo CM; Fan ST; Cheung ST
Oncotarget; 2016 Apr; 7(16):21644-57. PubMed ID: 26942873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
